Issued: 20 November 2026, London UK
Transfer of Treasury Shares
![]()
On 20 November 2026, GSK plc (the “Company”) transferred 22,000,000 ordinary shares of 31¼ pence each (“Ordinary Shares”) that were held by the Company in treasury (“Treasury Shares”) to JPMorgan Chase Bank, N.A., the depositary of the Company’s American depositary receipts (“ADR”) programme, to procure the issuance and transfer of 11,000,000 ADRs of the Company to the GlaxoSmithKline (US) Trust (the “Trust”), to be used to satisfy awards granted under the Company’s Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan. The consideration received from the trustee of the Trust, of $47.82 per ADR, representing $23.91 per Ordinary Share, was funded by a contribution to the Trust from GlaxoSmithKline LLC.
Following the transfer, the Company will hold 248,881,064 Ordinary Shares in treasury and have 4,067,451,066 Ordinary Shares in issue (excluding Treasury Shares).
The total number of voting rights in the Company is 4,067,451,066. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The Company confirms that, in accordance with DTR 5.5.1R, following the above transfer the percentage of voting rights attributable to the Treasury Shares is 6.12%.
This announcement is made in accordance with the requirements of UK Listing Rule 9.8.2.
Notifications may be sent to company.secretary@gsk.com.
V A Whyte
Company Secretary
20 November 2026
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG